Neurons expressing the serotonin 2A receptor (HTR2A) represent a crucial component of the serotonergic system in the brain. HTR2A is a Gq-coupled GPCR that mediates the effects of serotonin on pyramidal neurons, particularly in the prefrontal cortex. This receptor is of paramount importance in psychiatric pharmacology, being the target of atypical antipsychotics and psychedelic compounds, and is increasingly implicated in neurodegenerative disease processes.
HTR2A-expressing neurons are predominantly found in:
- Prefrontal Cortex: Layer V pyramidal neurons, especially in dorsolateral and medial PFC
- Anterior Cingulate Cortex: Involved in cognitive control and decision-making
- Motor Cortex: Layer V pyramidal neurons
- Somatosensory Cortex: Layer IV-V neurons
- Hippocampus: CA1 region, subiculum
- Amygdala: Basolateral complex, central nucleus
- Thalamus: Intralaminar nuclei, mediodorsal thalamus
- Brainstem: Raphe nuclei (some serotonin neurons co-express)
HTR2A is a 54-kDa GPCR with distinctive features:
- Gq/11 protein coupling, activating phospholipase C
- Generates IP3 and DAG second messengers
- Releases intracellular calcium
- Exhibits constitutive activity in some neuronal populations
- Undergoes homologous and heterologous desensitization
- Phosphorylation by GRKs and β-arrestin recruitment
- Alternative splicing generates receptor variants
- Modulates pyramidal neuron excitability
- Regulates glutamate release from presynaptic terminals
- Controls dendritic spine density and morphology
- Mediates cortical plasticity and learning
- Target of atypical antipsychotics (risperidone, clozapine, olanzapine)
- Mediates psychedelic effects of psilocybin and LSD
- Involved in antidepressant efficacy of some drugs
- Modulates emotional processing
- Working memory and executive function
- Decision-making and reward processing
- Attention and salience detection
- Social cognition
¶ Mood and Emotion
- Dysregulation linked to depression and anxiety
- Target for rapid-acting antidepressants
- Modulates stress responses
- Emotional memory processing
- 5-HT2A activation can have neuroprotective effects
- Modulates neuroinflammation
- Influences glial cell function
- Potential role in neuroplasticity
- HTR2A expression altered in AD brains, particularly in frontal cortex
- Some AD risk variants identified in HTR2A gene
- 5-HT2A antagonists being investigated
- Interaction with amyloid processing
- HTR2A in basal ganglia circuitry
- May contribute to levodopa-induced dyskinesias
- Target for psychosis in PD
- Modulates non-motor symptoms
- HTR2A polymorphisms associated with treatment response
- 5-HT2A antagonists (trazodone, nefazodone) have antidepressant effects
- Rapid-acting antidepressants work through 5-HT2A
- Target for treatment-resistant depression
- HTR2A polymorphisms affect risk and treatment response
- Atypical antipsychotics work primarily through 5-HT2A antagonism
- Normalizes cortical dysfunction
- Cognitive effects independent of dopamine
- 5-HT2A dysregulation in anxiety
- 5-HT2A agonists can be anxiogenic
- Some anxiolytics target 5-HT2A
- 5-HT2A activation can be pro- or anti-convulsant depending on brain region
- Altered expression in epileptic tissue
- Target for novel anti-epileptic drugs
HTR2A is a major drug target in psychiatry:
- Risperidone: FDA-approved for schizophrenia, bipolar, irritability in autism
- Clozapine: Treatment-resistant schizophrenia, off-label uses
- Olanzapine: Schizophrenia, bipolar disorder
- Quetiapine: Schizophrenia, depression
- Aripiprazole: Partial agonist, unique mechanism
- Trazodone: 5-HT2A antagonist, sleep and depression
- Nefazodone: 5-HT2A antagonist, depression
- Vortioxetine: Multi-modal including 5-HT2A antagonism
- Psilocybin: 5-HT2A agonist, treatment-resistant depression, anxiety
- LSD: Research in psychiatry
- 5-MeO-DMT: Clinical trials
- Ketanserin: Selective 5-HT2A antagonist, research tool
- M100907: Highly selective 5-HT2A antagonist
- 25CN-NBOH: Selective agonist
HTR2A serves as a biomarker:
- Genetic markers: HTR2A polymorphisms predict drug response
- Imaging: PET ligands for 5-HT2A (e.g., [11C]Cimbi-36)
- Expression: Peripheral platelet 5-HT2A as proxy
- Treatment predictor: Antipsychotic response
- HTR2A in Alzheimer's disease (2021)
- 5-HT2A receptors in Parkinson's disease (2020)
- Serotonin 2A receptor and psychedelic therapy (2022)
- Atypical antipsychotics: 5-HT2A mechanism (2021)
- HTR2A polymorphisms and antidepressant response (2020)
- 5-HT2A in cortical plasticity (2019)